Mural Oncology's stock plummeted 57% after halting the Phase 3 ARTISTRY-7 trial for nemvaleukin alfa. Click here to read an ...
Nitinotes, developer of EndoZip™, a fully automated endoscopic suturing system aimed at treating obesity, today announced that clinical research on the EndoZip™ system will be presented at upcoming ...
REDWOOD CITY, Calif., April 01, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced ...
FDA meeting to align on myositis registrational trial designs for rese-cel in 1H25 on track –– Enrolling approximately one patient per week ...
Dr. Surbhi Sidana discussed the topic of minimal residual disease during the CURE Educated Patient® Multiple Myeloma Summit.
Medera Inc. (“Medera”), a clinical-stage biopharmaceutical company focused on targeting cardiovascular diseases by developing ...
EpimAb Biotherapeutics, a clinical stage biotechnology company specializing in the development of bispecific antibodies and T ...
About Nuvectis Pharma, Inc. Nuvectis Pharma, Inc. is a biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical ...
Semaglutide, a glucagon-like peptide 1 (GLP-1) agonist, significantly improved maximal walking distance in people with ...
Session Date and Time: Monday, April 28, 2:00 - 5:00 p.m.
PHILADELPHIA, PA — Cabaletta Bio, Inc. (Nasdaq: CABA) has announced its financial results for the fourth quarter and full ...
The incidence of sudden cardiac arrest during marathons and half-marathons remained relatively stable over the past 2 decades ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback